Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cochlear neurotrophin gene therapy with cochlear implant for severe to profound hearing loss
ACTRN12618001556235Phase 2Completed
- Sponsor
- University of New South Wales
- Start
- Jan 2020
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of brain-derived neurotrophic factor plasmid DNA and neurotrophin-3 plasmid DNA in Hypoacusis and deafness, sponsored by University of New South Wales. Started Jan 2020; status: completed.
02
Drugs
brain-derived neurotrophic factor plasmid DNAneurotrophin-3 plasmid DNA
03
Conditions
Hypoacusisdeafness
Beyond the preview
Go deeper on ACTRN12618001556235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001556235.